Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs S-1 Adjuvant Therapy in Biliary Tract Cancer
NCT01815307Phase 2Completed
- Sponsor
- Kansai Hepatobiliary Oncology Group
- Start
- Jan 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, tegafur in biliary tract cancer (BTC), sponsored by Kansai Hepatobiliary Oncology Group. Started Jan 2013; status: completed.
02
Drugs
gemcitabinetegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01815307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815307.